LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aktien・Pfizer

Pfizer

Geschlossen

BrancheGesundheitswesen

25.9 0.04

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

25.9

Max

Schlüsselkennzahlen
By Trading Economics
Einkommen	4.3B 2.7B
Verkäufe	-3.1B 14B
KGV Branchendurchschnitt	19.336 49.701
EPS	0.75
Dividendenrendite	6.79
Gewinnspanne	18.656
Angestellte	75,000
EBITDA	4.5B 5.2B

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+12.63% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	6.79% 2.39%
Nächstes Ergebnis	4. Aug. 2026
Nächste Dividendenausschüttung	12. Juni 2026
Nächstes Ex-Dividendendatum	24. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-5.2B 144B
Vorheriger Eröffnungskurs	25.86
Vorheriger Schlusskurs	25.9

Nachrichtenstimmung

By Acuity

33%

67%

91 / 345 Ranking in Healthcare

Pfizer Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Pfizer Prognose

Kursziel

By TipRanks

12.63% Vorteil

12-Monats-Prognose

Durchschnitt 29.17 USD 12.63%

Hoch 36 USD

Tief 25 USD

Basierend auf 22 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pfizer – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

22 ratings

Buy

Halten

Sell

Basierend auf 22 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pfizer – Dist abgegeben haben.

Stimmung

By Acuity

91 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.